Indeed, GRHL2 has been identified as the FOXA1 interaction partner at the ER bound-active enhancer regions demarcated with H3K4me1/me2 marks to promote tumor progression (Jozwik et al., 2016). The gene discussed is GRHL2; the disease is neoplasm.